Richard C.E. Morgan, Chairman

Richard C.E. Morgan is Chief Executive Officer of Amphion Innovations plc, a London and New York based venture capital firm. Over the course of his career, Mr. Morgan has been directly involved in the start-up and development of more than 35 companies in the information technology, healthcare, and biotechnology industries. These include Celgene, which Mr. Morgan co-founded in 1987 and where he was on the board for over 20 years, serving on the executive committee and chairing the compensation committee until he stepped down in 2008. He was chairman for many years of MediSense, through its IPO and later through the completion of its acquisition by Abbott Labs for about $950 million. Mr. Morgan was also a board member and lead director of Sequus for many years through its acquisition by Alza for about $700 million. He was also formerly chairman of Quidel for many years and a board member of a number of private companies. Mr. Morgan was the Managing General Partner of Amphion Partners LLC (formerly known as Wolfensohn Partners, LP) a position which he retains, although the partnership is no longer active. Before joining Wolfensohn, Mr. Morgan spent 15 years with Schroders plc, a British merchant bank, where he was a member of the Board of the merchant bank and head of the Schroder Strategy Group, which he founded. Mr. Morgan, a British citizen, was raised in Kenya and educated in England. He graduated with a B. Engineering First Class Honors from the University of Auckland, New Zealand. In 1982 he completed the Advanced Management Program at the Harvard Business School. He is currently also Chairman of Axcess International, Inc., FireStar Software Inc., PrivateMarkets, Inc., and WellGen, Inc.

Graham Lumsden, Chief Executive Officer, Director

Graham Lumsden, Chief Executive Officer of Motif, is responsible for all aspects of the strategy, management, and operations of the Company. Prior to joining Motif, Mr. Lumsden was Worldwide Business Leader, Contraceptives and Osteoporosis at Merck & Co., Inc. where he previously held other international senior leadership roles as well as senior marketing positions. Mr. Lumsden has a proven record of success leading change and delivering results at Worldwide Vice President level including cross-functional team leadership, new product launches, pre-clinical / clinical development, regulatory strategy, IP strategy / litigation, and domestic / international sales and marketing. Mr. Lumsden is a member of the Royal College of Veterinary Surgeons (MRCVS), holds a masters from the Chartered Institute of Marketing (MCIM), and is a dual citizen of the U.S. and UK.

Robert Bertoldi, Director

Robert Bertoldi is President and CFO of Amphion Innovations. Mr. Bertoldi was a founder President and CFO of Amphion Capital Partners LLC (the predecessor company) and VennWorks LLC. Mr. Bertoldi is also a general partner of Amphion Partners LLC (formerly known as Wolfensohn Partners, LP). Prior to that, he served as Chief Financial Officer for James D. Wolfensohn, Inc. and Hambro America Inc. He began his career at KPMG and left as a manager in the investment services department. Mr. Bertoldi received a B.A. in Accounting and Economics from Queens College, New York in 1976 and became a Certified Public Accountant in 1978. He is a member of the AICPA and NYSCPA.

Bruce Williams, Non-Executive Director

Bruce Williams has significant operational experience in the Pharmaceutical and Biotech industries. Mr. Williams was an Executive Director of Ortho Biotech where he lead the marketing of Johnson & Johnson subsidiary’s lead product Procrit (epoetin alfa) from pre-approval through its sixth year in the market, to its first year of $1Billion (6th year).

Mr. Williams was previously Senior Vice President of sales and marketing at Celgene Corporation where he built the company’s commercial and distribution infrastructure to support the launch of its first product Thalomid (thalidomide). Mr. Williams was previously senior vice president, Sales and Marketing at Genta Incorporated where he lead the negotiation of a licensing and co-development/co-marketing agreement with Aventis for the company’s lead product. The company realized over $300 million in proceeds from this agreement. Mr. Williams currently serves on the boards of Motif and Afaxys Incorporated. He also Chairs the Board of Trustees of Rutgers Preparatory School, New Jersey’s first independent school.

Mary Lake Polan, M.D, Ph.D, MPH, Non-Executive Director

Mary Lake Polan, M.D., Ph.D., M.P.H., is a Clinical Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at Yale University School of Medicine. Dr. Polan specializes in reproductive endocrinology and infertility and hormonal issues related to gynecology patients and menopause. She received her bachelor’s degree from Connecticut College and her Ph.D. in Molecular Biophysics and Biochemistry and M.D. from Yale University and completed her residency and Reproductive Endocrine Fellowship in the Department of Obstetrics and Gynecology at the Yale University School of Medicine. Dr. Polan received her M.P.H. (Maternal and Child Health Programme) from the University of California, Berkeley.

Dr. Polan served on the board of Wyeth Pharmaceuticals prior to its acquisition by Pfizer and currently serves on the board of Quidel Corp, San Diego, CA and on the boards of several privately held life sciences companies. She chairs an SAB in Women’s Health for the Proctor and Gamble Company and several other advisory boards of private life sciences companies. She is also a Managing Director of Golden Seeds, an angel investing group which invests in women led companies.

Zaki Hosny, Non-Executive Director

Zaki Hosny is an independent consultant to life sciences companies. Mr. Hosny spent most of his career at Merck & Co in marketing and general management positions around the globe, including management responsibility for the company’s business in major markets in Europe. Mr. Hosny also held senior marketing roles with worldwide responsibility for cardiovascular and other franchises, and was closely involved in the clinical development of some of the company’s major products.

Mr. Hosny was Chief Executive Officer of Motif from 2006-13, and Deputy Chairman of its Board of Directors. Mr. Hosny is currently a Senior Advisor to the Albright Stonebridge Group, a strategic consultancy firm based in Washington, D.C. Mr. Hosny is also a consultant to Harel Consulting of New Jersey and Mettle Consulting of the UK. Mr. Hosny is based in Princeton, NJ and is a graduate of Cambridge University with an MA in history and law.

Charlotta Ginman, Non-Executive Director

Charlotta Ginman has substantial experience in financial and operational management gained during her career in investment banking and global telecommunications. Joining Ernst & Young and later appointed to senior roles with JP Morgan, Deutsche Bank and UBS, Ms. Ginman progressed to director of finance at Nokia Corporation, overseeing a number of acquisitions and led the successful sale of Nokia’s luxury mobile phone division, Vertu Corporation, to a private equity group. In addition to the her role at Motif she is also Non-Executive Director for Pacific Assets Plc, Polar Capital Technology Plc, Unicorn AIM VCT Plc and Consort Medical Plc as well as Chair of the Audit Committee for the first two. These are all UK based listed companies. A qualified chartered accountant in England and Wales, Ms. Ginman also holds an MSc in Economics from the Swedish School of Economics and Business Administration in Helsinki.

Jonathan E. Gold, Non-Executive Director

Jonathan Gold is a Managing Director of JEG Capital LLC, a family office and asset manager. Previously he was a Portfolio Manager for the Federated Kaufmann Funds from 2004 until 2012. The Federated Kaufmann Funds are aggressive growth mutual funds which currently have approximately $10B billion in assets under management. Prior to that Mr. Gold was a partner in Amphion Capital and Wolfensohn Partners (originally affiliates of James D. Wolfensohn Inc) where he was active in financing and growing early stage life sciences and information technology companies from 1995 to 2004. Early in his career, Mr. Gold was a financial analyst for Prudential’s Realty Group, which managed over $10 billion in equity real estate and over a $20 billion dollar portfolio of mortgages. Mr. Gold received his B.S. and MBA in Finance from New York University’s
Stern School of Business.